88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) confirmed a cash position of some A$6.8 million at the end of December as it today released its quarterly activities report.
The obligatory report for Australian-listed companies, as is customary, gave investors a rundown of the portfilio, and as such noted that 88 Energy had secured fourteen new Alaska North Slope leases covering 34,560 acres in the North Slope Fall 2025 bid round. It highlighted that seven of the leases are at South Prudhoe and cover about 16,640 acres.
Barkly Rare Earths (ASX: BAK) made a strong ASX debut today, jumping almost 50% to 29.5c in early trade after raising $8 million to fund work at its Barkly rare earths project in the Northern Territory. The company is up 30% a half hour before the close of its first trading session, sitting at 26 cents per share.
The IPO was priced at 20c a share late last year and was comfortably oversubscribed amid renewed focus on securing Western rare earth supply chains, with China again signalling potential export restrictions.
AuMEGA Metals Ltd (ASX:AAM, TSX:AUM, OTCQB:AUMMF, FRA:FRA: MA30) has released its quarterly activities report for the period ended 31 December 2025, outlining exploration progress and target generation across its district-scale landholding in Newfoundland and Labrador, Canada. All amounts are in Canadian dollars unless otherwise stated.
AuMEGA's non-executive chair Justin Osborne spoke with Proactive last week about the company’s focused exploration strategy in Newfoundland, Canada, where it controls about 110 kilometres of tenure along the highly prospective Cape Ray–Valentine Shear Zone. The structural corridor also hosts Equinox Gold’s 5Moz Valentine Gold Project, which has recently entered commercial production.
Recce Pharmaceuticals Ltd has reported solid operational momentum in its December 2025 quarter, highlighted by continued progress in its registrational Phase 3 clinical trial for diabetic foot infections (DFI) in Indonesia and encouraging new preclinical data for inhaled RECCE® 327 in hospital-acquired pneumonia models.
The company also strengthened its intellectual property position with a new Hong Kong patent grant and secured meaningful non-dilutive funding support through Australia’s R&D tax incentive framework.
Terra Metals Ltd (ASX:TM1, FRA:21V) has released its quarterly report for the period ending December 31, 2025, highlighting new discoveries at the Southwest Prospect within the Dante Project, continued resource upgrade and infill drilling at Reefs 1 and 2, and a strengthened balance sheet following a placement.
Initial assay results from the SW5 target returned high-grade PGE3 mineralisation of up to 52.97g/t PGE3, which the company says supports the Southwest Prospect emerging as a significant PGM–copper–nickel sulfide centre within Dante.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) advanced both its hydrogen shipping and CO₂ storage programs during the December 2025 quarter, strengthening commercial partnerships and progressing key technical milestones ahead of planned 2026 readiness.
The company said the quarter delivered tangible progress across its compressed hydrogen (H₂) and liquid CO₂ (LCO₂) platforms, underpinned by deeper engagement with strategic partners and resumed fabrication activity at its Norwegian robotics facility.
Cobalt Blue Holdings Ltd (ASX:COB, OTC:CBBHF, FRA:COH) says progress towards a final investment decision (FID) on its proposed Kwinana Cobalt Refinery (KCR) remained the central focus of a busy December 2025 quarter, as the company refreshed project economics, advanced offtake and financing discussions and strengthened its funding position with an oversubscribed capital raise.
Cobalt Blue told investors it completed a re-evaluation of KCR project parameters in response to structural changes in global cobalt markets during 2025. The updated approach narrows feedstock assumptions to cobalt hydroxide, expands the product mix to include cobalt metal alongside cobalt sulphate, and refreshes underlying economic assumptions ahead of FID.
Atomic Eagle Ltd (ASX:AEU, FRA:6QZ0) has outlined a significant boost in the scale of its flagship Muntanga Uranium Project in Zambia, declaring a substantial new Exploration Target and delivering encouraging results from maiden drilling programs completed during and shortly after the December 2025 quarter.
The company announced a JORC-compliant Exploration Target of 82 million–150 million tonnes (Mt) grading 150–350ppm U₃O₈ at Muntanga, equivalent to about 40 million–100.5 million pounds (Mlb) of contained uranium. The target sits in addition to Muntanga’s existing Mineral Resource base and highlights the project’s potential to grow materially beyond its current footprint.
Kairos Minerals Ltd (ASX:KAI, OTCQB:KAIFF, FRA:YAJ) has wrapped up its largest drilling program to date at the Mt York Gold Project in Western Australia, setting the stage for an updated mineral resource estimate (MRE) expected in the first half of calendar 2026.
The December 2025 quarter marked the completion of a 2025 drill campaign spanning the full 4.5-kilometre strike length of the Mt York gold system, with 128 reverse circulation and diamond holes drilled for 26,971 metres. The program was finalised ahead of the Pilbara summer and focused heavily on extending mineralisation at Main Hill, Gossan Hill and Breccia Hill.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) reported further positive clinical results during the December 2025 quarter, with its azer-cel Phase 1b trial achieving an Overall Response Rate of 82% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Of the 17 evaluable patients treated, 14 responded to therapy, including seven complete responses and seven partial responses. The company said responses were rapid, with best responses typically observed within one to three months, and noted that the first patient dosed in 2024 remains cancer-free more than 21 months later.
archTIS Ltd (ASX:AR9, OTCQB:ARHLF) reported continued momentum in the US defence market during the December 2025 quarter, with its NC Protect platform successfully deployed into a live Microsoft DoD365 production environment for the US Department of Defense.
During the period, the DoD’s systems integrator renewed 1,000 NC Protect production licences for a six-month term, moving the platform from pre-production evaluation into sustained operational use. archTIS also continued delivery of contracted development and integration services to support mission-specific capabilities within secure DoD365 environments, reinforcing its position within active defence workflows.
Solis Minerals Ltd (TSX-V:SLMN, ASX:SLM, OTCQB:SLMFF, FRA:08WA) has capped a busy December quarter with the acquisition of a large-scale copper porphyry system in Peru, steady drilling progress across its coastal exploration portfolio and a strengthened balance sheet to fund exploration through 2026.
The December 2025 quarterly report highlights the acquisition of the Cucho Copper Project, advancing drill programs at Ilo Este and Chancho al Palo, and the granting of drilling permits at Cinto, alongside a $5.9 million capital raise and completion of the company’s transition to the Australian market.
BOA Resources Ltd (ASX:BOA) completed its entry into Western Australia’s Murchison Copper Belt during the December 2025 quarter, acquiring a 49% interest in the Neds Creek copper project, which comprises 13 exploration licences covering about 1,140km².
The project sits within a proven copper province that hosts existing resources and historical mining operations and is considered underexplored relative to its geological potential. BOA has identified multiple copper targets at Neds Creek, including the advanced Ricci Lee prospect, located 2km southwest of the Thaduna Copper Deposit, which hosts 5.5Mt at 2.2% copper. Ricci Lee extends over about 500 metres and has returned ore-grade copper intercepts, with the company planning to prioritise the prospect for resource definition drilling.
Prescient Therapeutics Ltd (ASX:PTX) reported meaningful regulatory progress during the December 2025 quarter, with the European Medicines Agency granting Orphan Drug Designation for PTX-100 for the treatment of cutaneous T-cell lymphoma (CTCL). The designation covers both mycosis fungoides and Sézary syndrome and is expected to provide 10 years of market exclusivity in the European Union following marketing approval.
The company also received authorisation through the European Clinical Trials Information System to initiate its Phase 2a clinical trial in relapsed or refractory CTCL, enabling site activation and patient recruitment across Europe.
Sovereign Metals Ltd (ASX:SVM, OTC:SVMLF, AIM:SVML, FRA:SVM) has reported a pivotal December 2025 quarter marked by the recovery of high-value heavy rare earth elements from its flagship Kasiya Rutile-Graphite Project in Malawi — a development that could add a third revenue stream to the globally significant critical minerals project at minimal additional cost.
The company confirmed it has successfully recovered a monazite concentrate containing elevated levels of dysprosium, terbium and yttrium from the rutile tailings stream at Kasiya, with preliminary analysis showing heavy rare earth grades materially exceeding those of the world’s five largest rare earth producers.
Janus Electric Holdings Ltd (ASX:JNS) reported operational income of $896,000 for the three months to December 31, 2025, up 190% on the prior period, as the heavy-vehicle electrification group pointed to improving operating performance and initial export orders to California.
Truck conversion and charge station sales totalled $472,000 for the quarter, with a further $1.558 million recorded as deferred revenue. The remaining $424,000 was attributed to recurring and subscription revenue linked to charging stations and its batteries-as-a-service offering.
Nexus Minerals Ltd (ASX:NXM, FRA:YAK) has progressed permitting and operational readiness work at its Crusader–Templar gold deposit at the Wallbrook Gold Project in Western Australia, while reporting high-grade drilling results that it says have advanced multiple regional prospects toward resource definition.
In its quarterly activities report for the period ended 31 December 2025, the company said further permitting approvals had been received for Crusader–Templar and discussions were continuing with potential operational and toll treatment partners, as Nexus assesses development pathways for what it describes as a multi-stage, multiple open pit opportunity.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has closed the December 2025 quarter with its lead oncology program HMBD-002 positioned to move into phase II testing, following the release of final phase I data and completion of detailed planning for the next stage of clinical development.
The quarter was marked by the presentation of full results from HMBD-002’s completed phase I study, confirmation of a favourable safety profile, and the release of a modular phase II trial design aimed at accelerating data read-outs across multiple tumour types.
Critical Resources Ltd (ASX:CRR, FRA:9S70) has reported progress across its lithium, gold and battery-technology portfolio during the quarter ended December 31, 2025, including land consolidation at its flagship Canadian lithium project, inaugural drilling in New Zealand and corporate funding activity.
At the Mavis Lake Lithium Project in Ontario, Critical Resources expanded its landholding to more than 400km², securing a consolidated position across several structurally controlled lithium corridors considered prospective for spodumene-hosted mineralisation.
Lightning Minerals Ltd (ASX:L1M, FRA:YZ1) has kicked off exploration at its Mt Turner project in Queensland with a highly successful maiden drill program in the December quarter, confirming gold and base metal mineralisation in every hole drilled and setting the stage for a second phase of drilling in early 2026.
The December quarter marked a step-change for the company, with its first nine-hole drill campaign intersecting multiple zones of high-grade epithermal gold alongside strong zinc, lead and silver mineralisation. Follow-up soil and rock chip sampling has expanded the project’s target footprint, while a $2.5 million capital raise has fully funded the next phase of exploration. The company also strengthened its board during the quarter with the appointment of experienced mining executive David Vilensky as non-executive chairman.